Eastbourne Capital May Talk With Amylin Pharma (AMLN) About A Possible Sale

In an amended 13D filing on Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), hedge fund Eastbourne Capital disclosed that they plan to have discussions with management and others on actions that may enhance shareholder value, including a possible acquisition of the company by a third party.

Eastbourne Capital disclosed a 12.5% stake in Amylin in August.

Amylin has seen it stock drop 70% this year as the company's BYETTA diabetes drug has been linked to pancreatitis.

Activist investor Carl Icahn, a 7.3% shareholder, has also tried to convince Amylin to explore a sale.

You May Also Be Interested In

• Mavis acquires Pep Boys from Icahn Enterprises for $700M